US$ 26.60
glp 1 agonist uses GLP-1 Receptor Shortage: Challenges and Solutions in Type 2 Diabetes Care GLP-1 Receptor Agonists | New
Description
Glucagon-like peptide-1 (GLP-1), as one of the important targets for the treatment of type 2 diabetes mellitus (T2DM), has obvious therapeutic effect, short half-life and easy to be cleared

GLP-1s are an approved treatment for those with a BMI over 30, or a BMI over 27 with at least one comorbidity like type 2 diabetes, hypertension or sleep apnea

Reducing fat-driven inflammation Fat tissue releases inflammatory chemicals

Youve likely heard buzz (and seen commercials) about GLP-1 drugs for weight management, like semaglutide (Wegovy) or tirzepatide (Zepbound)

Similarly, 100nM Semaglutide promoted osteogenesis in rat BMSC via WNT-beta-Catenin signaling, which resulted in promoted mineral deposition and RUNX2/OCN gene expression [30]

[DOI] [PubMed] [Google Scholar] 2.Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW
